Register
Medicines reference
Product

Enroxil Flavour

Enrofloxacin · KRKA-Farma d.o.o.

1 form: scored tablet. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
50 mg, Scored tablet · Dog Dog 1 tablet per 10 kg
Enrofloxacin 5 mg/kg/day PO: one 50 mg tablet per 10 kg body weight daily, with or without food. Measure body weight accurately and do not exceed the dose. Extend beyond 10 days only after clinical reassessment and veterinary judgement. The tablet is validated for halves only: one half is 25 mg and fits a 5 kg step at this regimen. Return a half-tablet to the opened blister and use within 24 hours; do not infer quartering or crushing accuracy.
· once daily or the daily amount divided into two administrations, for 5-10 days
once daily or the daily amount divided into two administrations, for 5-10 days Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ენროქსილ ფლეივორი 50 მგ
№ 162-11; 15-11
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Enroxil Flavour 50 mg, Scored tablet

enrofloxacin 50 mg, scored tablet for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.6/10
Good
vetman assessment

Enroxil Flavour

50 mg, enrofloxacin 50 mg, scored tablet for dogs
Assessed clinical scopeDog · Complete dog label: oral treatment of susceptible bacterial alimentary, respiratory, urogenital, skin, secondary-wound and otitis externa infections when enrofloxacin is the justified drug of choice · By mouth
Care settingOutpatient reserve-antimicrobial treatment after diagnosis and accurate weighing, with susceptibility testing whenever possible and planned clinical reassessment
vetman score 7.6/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 162-11; 15-11 · Verified on 22 Oct 2026

A well-documented, practical oral enrofloxacin presentation for an accurately diagnosed susceptible infection in an adult dog. Its value is good—not routine—because fluoroquinolones are Category B Restrict and should follow susceptibility-led justification when lower-category effective options are unsuitable.

Regulatory and scientific credibility9.0/10

The exact 50 mg presentation has current transparent EU and Georgian authorisations plus a current aligned KRKA GB authorisation/SPC. FDA-approved oral enrofloxacin products independently support the active/form endpoint, although this exact KRKA presentation is not FDA approved.

Clinical efficacy7.0/10

Enrofloxacin has established concentration-dependent activity and an exact authorised 5 mg/kg regimen across the susceptible dog label. Benefit remains organism-, site- and susceptibility-dependent; resistance and modern syndrome guidance make it a reserve rather than broad empirical default, and independent exact-generic outcome data across every bundled indication are limited.

Safety and tolerability6.5/10

Correctly selected adult dogs usually have a workable margin and very rare anorexia/vomiting, but rapid-growth cartilage injury, seizure/CNS risk, renal/hepatic caution, milk transfer, overdose without an antidote and clinically important antimicrobial, theophylline, anticoagulant and chelation interactions are material.

Clinical practicality8.0/10

Once-daily dosing, food flexibility, a 5-10-day course and half-tablet division are practical for correctly sized dogs. The 50 mg tablet supplies validated 5 kg steps only; smaller or intermediate doses need a more suitable strength rather than quarters/crushing, and a used half expires after 24 hours.

Full-course cost-effectiveness-

Current Georgian full-course price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Scope boundary: this is one assessment of the complete authorised susceptible-infection dog scope. It does not endorse prophylaxis, undiagnosed non-bacterial disease, every listed organism without susceptibility, cats or another enrofloxacin strength/formulation.
  • Stewardship hard stop: fluoroquinolones are EMA AMEG Category B (Restrict). Prefer an effective Category D/C or narrower option; use culture/susceptibility whenever possible and document why enrofloxacin is the justified choice.
  • Do not use in dogs under one year or exceptionally large breeds under 18 months: articular cartilage can be affected during rapid growth. Joint-cartilage disorder has an undetermined frequency.
  • Do not use in dogs with seizure disorders because CNS stimulation can occur. Stop and reassess neurologic or behavioural change; overdose can cause GI and CNS signs and has no specific antidote.
  • Use caution in severe renal or hepatic impairment and do not exceed 5 mg/kg/day. Weigh accurately and reassess exposure, response and organ function where clinically indicated.
  • Very rare anorexia and vomiting are reported. Reassess persistent GI signs, treatment failure, superinfection or clinical deterioration; source control and diagnosis matter more than blind dose escalation.
  • Do not combine with tetracyclines, phenicols or macrolides because of potential antagonism. Review oral anticoagulants and theophylline; separate or otherwise manage magnesium/aluminium products because absorption may be delayed.
  • Exact dose: 5 mg/kg/day PO for 5-10 days, once daily or the daily amount divided twice, with or without food. The 50 mg tablet equals 10 kg and validates halves only; do not invent quarters, crush-derived doses or the US 5-20 mg/kg range.
  • Enrofloxacin passes into milk; use during lactation only after veterinary benefit-risk assessment. The current exact SPC provides no separate pregnancy assurance, so do not infer pregnancy safety.
  • Return a half-tablet to the opened blister and use within 24 hours. Wash hands, avoid contact after known quinolone hypersensitivity and seek medical advice after accidental ingestion.
Assessment sources
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ენროქსილ ფლეივორი 50 მგ
№ 162-11; 15-11
Verified on: 22 Oct 2026
EU Yes, veterinary
№ UP/I-322-05/20-01/513
Verified on: 22 Oct 2026
UK Yes, veterinary
№ Vm 01656/4008
Verified on: 22 Oct 2026
US No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Prescription-only reserve fluoroquinolone. For diagnosed susceptible infections within the authorised dog scope when enrofloxacin is the justified choice, preferably supported by culture/susceptibility. Give 5 mg/kg/day PO for 5-10 days, once daily or as the daily amount divided twice, with or without food. One 50 mg tablet/10 kg; halves only. Weigh accurately, reassess before extending and use a returned blistered half within 24 hours.
DoseSpeciesWeightRouteFrequencySource
1 tablet per 10 kg
Enrofloxacin 5 mg/kg/day PO: one 50 mg tablet per 10 kg body weight daily, with or without food. Measure body weight accurately and do not exceed the dose. Extend beyond 10 days only after clinical reassessment and veterinary judgement. The tablet is validated for halves only: one half is 25 mg and fits a 5 kg step at this regimen. Return a half-tablet to the opened blister and use within 24 hours; do not infer quartering or crushing accuracy.
Dog Any weight By mouth once daily or the daily amount divided into two administrations, for 5-10 days
EU SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Enroxil Flavour 50 mg tablets for dogs - Summary of Product Characteristics
EU Union Product Database, 2025

Known Contraindications

  • Critical
    Do not use enrofloxacin in animals with epilepsy, seizures, or seizure disorders associated with the central nervous system, because it may stimulate the CNS.
    Sources: VMD SPC · VMD · FDA
  • Critical
    Do not use in animals hypersensitive to the active substance, another fluoroquinolone, or any excipient. Do not use against known quinolone resistance because cross-resistance is extensive. Treat Pseudomonas infections only after susceptibility testing.
    Sources: VMD SPC · VMD
  • Critical (Dog)
    Not for use in dogs less than 1 year of age or in exceptionally large breeds of dog with a longer growth period under 18 months of age. has not been established
    Sources: VMD · FDA
  • Warning
    Elimination may be delayed in animals with pre-existing renal damage. Use with caution in severe renal or hepatic impairment.
    Sources: VMD SPC · VMD
  • Warning
    Use with caution in severe hepatic impairment. Concomitant administration with other hepatically metabolized medicines may reduce clearance of both the quinolone and the other medicine.
    Sources: VMD SPC · VMD · FDA
  • Warning
    The use is not recommended during pregnancy The safety of the veterinary medicinal product has not been established during pregnancy and lactation Safety in breeding or pregnant cats has not been established The veterinary medicinal product may be used safely in pregnant and lactating animals
    Sources: VMD · FDA
  • Warning
    the use is not recommended during lactation may be used safely in pregnant and lactating animals
    Sources: VMD

Known Drug Interactions

  • Major warning Enrofloxacin + Aminophylline
    Theophylline metabolism is inhibited by erythromycin, cimetidine, propranolol, enrofloxacin, and marbofloxacin
    Recommendation: Reduce the aminophylline dose during concomitant use. Signs of toxicity include vomiting, excitation, tachyarrhythmia, and seizures.
    Sources: MSD Vet Manual
  • Major warning Enrofloxacin + Doxycycline
    Do not combine enrofloxacin with antimicrobials that act antagonistically to quinolones, including macrolides, tetracyclines such as doxycycline, and phenicols such as chloramphenicol.
    Recommendation: Do not administer concurrently. Based on susceptibility testing, choose either a bactericidal fluoroquinolone or a bacteriostatic tetracycline.
    Sources: VMD SPC · VMD
  • Major warning Enrofloxacin + Theophylline
    Do not use concurrently with theophylline as the elimination of theophylline may be delayed Concomitant administration of theophylline requires careful monitoring as serum levels of theophylline may increase
    Recommendation: Avoid the combination where possible. If concomitant use is unavoidable, monitor serum theophylline and be prepared to reduce its dose.
    Sources: VMD
  • Minor warning Enrofloxacin + Sucralfate
    The concomitant administration of substances containing magnesium or aluminium may reduce the absorption of enrofloxacin. These drugs should be administered two hours apart.
    Recommendation: Separation is not critical in dogs, but a 2-hour interval is safe and label-consistent. No comparable measurement exists in cats; use a 2-hour interval in cats.
    Sources: VMD SPC · VMD · JVIM

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.